Celestia S Higano

发表

Intermittent versus continuous androgen deprivation in prostate cancer.

Donna L Berry, Ian M Thompson, Stephen Prescott, 2013, The New England journal of medicine.

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

Thomas Wiegel, Colin C Pritchard, Stefano Fanti, 2018, European urology.

Featured Updates to the NCCN Guidelines

Charles A Enke, James L Mohler, Michael Kuettel, 2013 .

Quantitative mathematical modeling of PSA dynamics of prostate cancer patients treated with intermittent androgen suppression.

Kazuyuki Aihara, Yoshito Hirata, Nicholas Bruchovsky, 2012, Journal of molecular cell biology.

Relationships between times to testosterone and prostate-specific antigen rises during the first off-treatment interval of intermittent androgen deprivation are prognostic for castration resistance in men with nonmetastatic prostate cancer.

Roman Gulati, C. Higano, Rachel Hunter-Merrill, 2015, Clinical genitourinary cancer.

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.

Susan Halabi, Ian F Tannock, Ian M Thompson, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation.

Donatello Telesca, Roman Gulati, P. Nelson, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.

Anthony V D'Amico, Javier Hernandez, Arthur L Burnett, 2007, The Journal of urology.

Intermittent androgen suppression for rising PSA level after radiotherapy.

Fred Saad, Emma Hall, Graeme Duncan, 2012, The New England journal of medicine.

Real‐world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer

Hong Tang, Matthew R Cooperberg, Andrew J Armstrong, 2019, Cancer.

Prostate Cancer, Version 1.2016.

Christopher J Kane, Charles A Enke, James L Mohler, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Erectile function outcome reporting after clinically localized prostate cancer treatment.

Anthony V D'Amico, Javier Hernandez, S Larry Goldenberg, 2007, The Journal of urology.

Personalizing Androgen Suppression for Prostate Cancer Using Mathematical Modeling

Kazuyuki Aihara, Kai Morino, Yoshito Hirata, 2018, Scientific Reports.

Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer.

Roman Gulati, C. Higano, E. Yu, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone.

Hubert Vesselle, Paul Lange, Lawrence D True, 2003, Human pathology.

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.

P. Schellhammer, C. Redfern, J. Nemunaitis, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines.

Charles A Enke, James L Mohler, Thomas Farrington, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.